Mesoblast (NASDAQ: MESO)
Mesoblast Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Mesoblast Company Info
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
News & Analysis
Why Shares of Mesoblast Are Down Monday
The company's shares continued to tumble after it received a Complete Response Letter last week from the FDA.
Why Shares of Mesoblast Are Plunging Friday
The company received a Complete Response Letter from the FDA regarding its prospective graft-versus-host disease therapy.
Why Mesoblast Limited Stock Is Jumping Today
The company announced positive results from a clinical trial.
Why Mesoblast Limited Is Rising Today
One of its pipeline candidates achieved great results in a late-stage clinical study.
Why Mesoblast Stock Skyrocketed Today
The company announced positive results from a clinical trial.
Why Mesoblast Stock Plummeted on Friday
Investors are losing confidence because the company disappointed in a late-stage trial for the second time this week.
Why Mesoblast Stock Is Tanking Today
The company reported disappointing results from a late-stage clinical study.
Why Mesoblast Stock Is Blasting Off Today
Investors are excited about the biotech's new collaboration with Novartis.
Valuation
Earnings Transcripts
Mesoblast Limited (MESO) Q1 2022 Earnings Call Transcript
MESO earnings call for the period ending December 31, 2021.
Mesoblast (MESO) Q3 2021 Earnings Call Transcript
MESO earnings call for the period ending June 30, 2021.
Mesoblast (MESO) Q3 2021 Earnings Call Transcript
MESO earnings call for the period ending March 31, 2021.
Mesoblast (MESO) Q1 2021 Earnings Call Transcript
MESO earnings call for the period ending September 30, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.